scholarly journals Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review

2013 ◽  
Vol 5 (3) ◽  
pp. 120 ◽  
Author(s):  
Simona Bota
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Adverse Events ◽  
Antiviral Therapy ◽  
Cirrhotic Patients ◽  
Severe Adverse Events

Liver Transplantation and Hepatitis C Virus: Systematic Review of Antiviral Therapy

2005 ◽  
Vol 79 (3) ◽  
pp. 261-268 ◽  
Author(s):  
Christos Triantos ◽  
Dimitrios Samonakis ◽  
Rosa Stigliano ◽  
Ulrich Thalheimer ◽  
David Patch ◽  
...  
Keyword(s):  
Systematic Review ◽  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy

scholarly journals An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0246594
Author(s):  
Sara Majd Jabbari ◽  
Khadije Maajani ◽  
Shahin Merat ◽  
Hossein Poustchi ◽  
Sadaf G. Sepanlou
Keyword(s):  
Chronic Kidney Disease ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Kidney Disease ◽  
Adverse Events ◽  
Meta Analysis ◽  
Virologic Response ◽  
Svr12 Rate ◽  
Advanced Chronic Kidney Disease ◽  
Cirrhotic Patients

Sofosbuvir seems to be a revolutionary treatment for Hepatitis C-infected patients with advanced chronic kidney disease (CKD) but existing evidence is not quite adequate. The aim of this study was to evaluate the efficacy and safety of Sofosbuvir-based therapy without Ribavirin for all hepatitis C virus genotypes among patients with advanced CKD. We conducted an updated systematic literature search from the beginning of 2013 up to June 2020. Sustained virologic response (SVR) rate at 12 and/or 24 weeks after the end of treatment, and adverse events in HCV-infected patients with advanced CKD were pooled using random effects models. We included 27 published articles in our meta-analyses, totaling 1,464 HCV-infected patients with advanced CKD. We found a substantial heterogeneity based on the I2 index (P = 0.00, I2 = 56.1%). The pooled SVR rates at 12 and 24 weeks after the end of Sofosbuvir-based treatment were 97% (95% Confidence Interval: 95–99) and 95% (89–99) respectively. The pooled SVR12 rates were 98% (96–100) and 94% (90–97) in patients under 60 and over 60 years old respectively. The pooled incidence of severe adverse events was 0.11 (0.04–0.19). The pooled SVR12 rate after completion of the half dose regimen was as high as the full dose treatment but it was associated with less adverse events (0.06 versus 0.14). The pooled SVR12 rate was 98% (91–100) in cirrhotic patients and 100% (98–100) in non-cirrhotic patients. The endorsement of Sofosbuvir-based regimen can improve the treatment of hepatitis C virus infection in patients with advanced CKD.

Mortality and Severe Adverse Events of Pegylated-Inteferon Plus Ribavirin Therapy for Chronic Hepatitis C: A Systematic Review

2011 ◽  
Vol 140 (5) ◽  
pp. S-454-S-455
Author(s):  
Takahiro Kishikawa ◽  
Tatsuya Minami ◽  
Masaya Sato ◽  
Ryosuke Tateishi ◽  
Haruhiko Yoshida ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Adverse Events ◽  
Chronic Hepatitis C ◽  
Severe Adverse Events

Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection

2011 ◽  
Vol 9 (7) ◽  
pp. 602-608.e1 ◽  
Author(s):  
Thomas Reiberger ◽  
Karoline Rutter ◽  
Arnulf Ferlitsch ◽  
Berit Anna Payer ◽  
Harald Hofer ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Antiviral Therapy ◽  
Portal Pressure ◽  
Hepatitis C Virus Infection ◽  
Cirrhotic Patients

scholarly journals Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review

2017 ◽  
Vol 1 (5) ◽  
pp. 379-390 ◽  
Author(s):  
Sofia R. Bartlett ◽  
Jason Grebely ◽  
Auda A. Eltahla ◽  
Jacqueline D. Reeves ◽  
Anita Y.M. Howe ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Direct Acting Antiviral ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document